6 versus 12 months of adjuvant trastuzumab in patients with HER2 positive breast cancer (PERSEPHONE): definitive 4-year disease-free survival results of an open label …
user-5d8054e8530c708f9920ccce（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要